Inspra

 

Topic mentions per year

Topic mentions per year

2003-2016
012320032016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Long-lasting postoperative macular edema is a therapeutic challenge. The authors report an efficient combination therapy of oral… (More)
Is this relevant?
2016
2016
To evaluate the effect of oral spironolactone and eplerenone, two specific antagonists of the mineralocorticoid receptor, in… (More)
Is this relevant?
2013
2013
Eplerenone (Inspra) is an aldosterone receptor antagonist approved for the treatment of hypertension and heart failure after a… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 5
Is this relevant?
Review
2006
Review
2006
Eplerenone (Inspra, Pfizer, New York, USA), a 9,11epoxy derivative of spironolactone, is the second aldosterone antagonist… (More)
Is this relevant?
Review
2005
Review
2005
Eplerenone (Inspra) is a selective aldosterone blocker. When added to standard medical therapy, eplerenone significantly improved… (More)
Is this relevant?
2004
2004
Eplerenone is the second oral aldosterone antagonist available in the USA for the treatment of essential hypertension and heart… (More)
  • table 1
  • table 2
Is this relevant?
2004
2004
Since the isolation and purification of aldosterone from adrenal extracts 50 years ago (Experientia 9 (1953) 33), scientists have… (More)
Is this relevant?
2004
2004
 
Is this relevant?
Review
2004
Review
2004
The classical mineralocorticoid effect of aldosterone on unidirectional transepithelial sodium transport in the kidney was long… (More)
Is this relevant?
2003
2003
Since neither angiotensin-converting enzyme inhibitors (ACE-I) nor angiotensin II receptor blockers (ARB) can completely suppress… (More)
Is this relevant?